Jessica Ochalek

Jessica Ochalek

Auto-generated profile, based on publicly available information

Jessica Ochalek

Centre for Health Economics, University of York, York, UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2018 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
JOJessica Ochalek
Jessica Ochalek
JLJames Lomas
James Lomas
KCKarl Claxton
Karl Claxton
The economic evaluation of healthcare interventions requires an assessment of whether the improvement in health outcomes they offer exceeds the improvement in health that would have been possible if the additional resources required had, instead, been made available for other healthcare activities. Therefore, some assessment of these health opportunity costs is required if the best use is to be made of the resources available for healthcare. This paper provides a framework for generating country-specific estimates of cost per disability-adjusted life year (DALY) averted ‘thresholds’ that reflect health opportunity costs. We apply estimated elasticities on mortality, survival, morbidity and a generic measure of health, DALYs, that take account of measures of a country’s infrastructure and changes in donor funding to country-specific data on health expenditure, epidemiology and demographics to determine the likely DALYs averted from a 1% change in expenditure on health. The resulting range of cost per DALY averted ‘threshold’ estimates for each country that represent likely health opportunity costs tend to fall below the range previously suggested by WHO of 1–3× gross domestic product (GDP) per capita. The 1–3× GDP range and many other previous and existing recommendations about which interventions are cost-effective are not based on an empirical assessment of the likely health opportunity costs, and as a consequence, the health effects of changes in health expenditure have tended to be underestimated, and there is a risk that interventions regarded as cost-effective reduce rather than improve health outcomes overall.

28 August 2020 in PharmacoEconomics
Verified
Journal Article
Closed access
PDF file
JOJessica Ochalek
Jessica Ochalek
HWHaiyin Wang
Haiyin Wang
YGYuanyuan Gu
Yuanyuan Gu
JLJames Lomas
James Lomas
HCHenry Cutler
Henry Cutler
CJChunlin Jin
Chunlin Jin

9 April 2018 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
JOJessica Ochalek
Jessica Ochalek
PRPaul Revill
Paul Revill
GMGerald Manthalu
Gerald Manthalu
FMFinn McGuire
Finn McGuire
DNDominic Nkhoma
Dominic Nkhoma
KCKarl Claxton
Karl Claxton
Malawi, like many low-income and middle-income countries, has used health benefits packages (HBPs) to allocate scarce resources to key healthcare interventions. With no widely accepted method for their development, HBPs often promise more than can be delivered, given available resources. An analytical framework is developed to guide the design of HBPs that can identify the potential value of including and implementing different interventions. It provides a basis for informing meaningful discussions between governments, donors and other stakeholders around the trade-offs implicit in package design. Metrics of value, founded on an understanding of the health opportunity costs of the choices faced, are used to quantify the scale of the potential net health impact (net disability adjusted life years averted) or the amount of additional healthcare resources that would be required to deliver similar net health impacts with existing interventions (the financial value to the healthcare system). The framework can be applied to answer key questions around, for example: the appropriate scale of the HBP; which interventions represent ‘best buys’ and should be prioritised; where investments in scaling up interventions and health system strengthening should be made; whether the package should be expanded; costs of the conditionalities of donor funding and how objectives beyond improving population health can be considered. This is illustrated using data from Malawi. The framework was successfully applied to inform the HBP in Malawi, as a core component of the country’s Health Sector Strategic Plan II 2017–2022.

29 September 2021 in PharmacoEconomics
Verified
Journal Article
Closed access
PDF file
LELaura Catherine Edney
Laura Catherine Edney
JLJames Lomas
James Lomas
JKJonathan Karnon
Jonathan Karnon
LVLaura Vallejo-Torres
Laura Vallejo-Torres
NSNiek Stadhouders
Niek Stadhouders
JOJessica Ochalek
Jessica Ochalek

20 October 2020 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
JOJessica Ochalek
Jessica Ochalek
KAKaja Abbas
Kaja Abbas
KCKarl Claxton
Karl Claxton
MJMark Jit
Mark Jit
JLJames Lomas
James Lomas
Introduction Estimating the value of providing effective healthcare interventions in a country requires an assessment of whether the improvement in health outcomes they offer exceeds the improvement in health that would have been possible if the resources required had, instead, been made available for other healthcare activities in that country. This potential alternative use of the same resources represents the health opportunity cost of providing the intervention. Without such assessments, there is a danger that blanket recommendations made by international organisations will lead to the adoption of healthcare interventions that are not cost effective in some countries, even given existing donor mechanisms intended to support their affordability. Methods We assessed the net health impact to 46 Gavi-eligible countries of achieving one of the WHO’s proposed 90-70-90 targets for cervical cancer elimination, which includes 90% coverage of human papillomavirus (HPV) vaccination among girls by 15 years of age, using published estimates of the expected additional benefits and costs in each country and estimates of the marginal productivity of each healthcare system. We calculated the maximum price each country could afford to pay for HPV vaccination to be cost effective by assessing the net health impact that would be expected to be generated at different potential prices. Results At Gavi negotiated prices, HPV vaccination offers net health benefits across most Gavi-eligible countries included in this study. However, if Gavi-eligible countries faced the average price faced by non-Gavi eligible countries, providing HPV vaccination would result in reduced overall population health in most countries. Conclusion Estimates of the net health impact of providing a healthcare intervention can be used to assess the benefit (or lack of) to countries of adhering to global guidance, inform negotiations with donors, as well as pricing negotiations and the value of developing new healthcare interventions.

18 January 2023 in Journal of Medical Economics
Verified
Journal Article
Open access
AAAhmed Al-Jedai
Ahmed Al-Jedai
JLJames Lomas
James Lomas
HAHajer Yousef Almudaiheem
Hajer Yousef Almudaiheem
YAYazed AlRuthia
Yazed AlRuthia
SAShabab Alghamdi
Shabab Alghamdi
JOJessica Ochalek
Jessica Ochalek
Healthcare in Saudi Arabia is undergoing wide-ranging reform through Saudi Arabia’s Vision 2030. One aim of these reforms is to ensure that money spent on healthcare generates the most improvement in population health possible. To do this requires understanding the trade-offs that exist: funding one pharmaceutical drug means that same money is not available to fund another pharmaceutical drug. This is relevant whether the new drug would be funded from within the existing budget for healthcare or from an expansion of it. If the drugs apply to the same patient population and have the same price, the question is simply, “which one generates more health?” In reality, we need to compare pharmaceutical drugs for different diseases, patient populations, and at a range of potential prices to understand whether the drug in question would generate more health per riyal spent than what is currently funded by the healthcare system. This paper provides the first estimates of the amount of health, measured in terms of quality adjusted life years (QALYs), generated by the Saudi Arabian healthcare system. We find that the healthcare system generates health at a rate of one QALY produced for every 50,000 to 75,000 riyals spent (58% to 86% of GDP per capita). Using the range we estimate to inform cost-effectiveness threshold can aid decision-making.